Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Federico II University350 enrolled

Overview

This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

106 Ruthenium Plaque Brachytherapy Uveal Melanoma

Interventions

106 Ruthenium plaque brachytherapyRADIATION

All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age older than 40 years * diagnosis of uveal melanoma Exclusion Criteria: * age older than 80 years * No diagnosis of uveal melanoma

Locations (1)

University of Naples "Federico II"

Naples, Italy

Outcomes

Primary Outcomes

To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma

To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival

Time frame: Mean follow-up was 4 years (3 months-9 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.